Regenerative Medicine Market to Gain from Rising Prevalence of Complicated Degenerative Disorders Such as Age-Related Macular Degeneration

Regenerative medicine is a comparatively new area of science that involves the restoration of damaged cells, tissues or organs by applying cell therapy, tissue engineering, immunotherapy or gene therapy techniques. On contrary to the present clinical therapeutics that act on slowing the disease progression or relieve symptoms, regenerative medication has a promising therapeutic approach of restoring the function and structure of damaged organs and tissues. The global regenerative medicine market is expected to witness significant growth during the forecast period (2017–2023), due to the increase in the prevalence of chronic diseases, orthopaedic injuries, genetic disorders, growing aging population, increasing government funding along with the private funding in the research & development of regenerative medicines with the advancement in nanotechnology based drug delivery system, and moderate healthcare reforms.



Technological innovations in the area of stem cell therapy and tissue engineering has led to rapid growth of the regenerative medicine market size. The key factors which drive the growth of the global market include increase in the demand of orthopaedic surgeries, government healthcare reforms in certain countries such as the U.S. and Canada, aging population, rise in chronic diseases, increasing prevalence of bone and joint diseases, and innovations in nanotechnology that aids in drug delivery mechanism.


However, stringent regulations, ethical issues, and the risk of product failure and their recall are the key barriers for the growth of the regenerative medicine market. The cost of regenerative medicine treatment is significantly high and it is less effective in case of geriatric patients, which hinders the growth of the global market to some extent.


Key companies are acquiring other companies to strengthen their regenerative medicine market share. For instance, in August 2016, Medtronic Inc. had acquired Heart Ware International, Inc., that offers less-invasive, miniaturized, mechanical circulatory support (MCS) techniques as an advanced heart failure treatment. This acquisition was aimed at increasing the working efficiency of the company and to broaden its product portfolio.

Some of the other key players operating in the global market include Acelity L.P. Inc., NuVasive Inc., Vericel Corporation, Osiris therapeutics Inc., Integra Lifesciences Corporation, Stryker Corporation, Cook Biotech Incorporated, Organogenesis Inc., and Japan Tissue Engineering Co. Ltd.
Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook

Comments

Popular posts from this blog

How is Booming Life Sciences Sector Contributing to Growth of Saudi Microbiology Cell Culture Market?

Government and International Organizations Investing Heavily in Synthetic Biology

How is Increasing Focus on Personalized Medicine Driving Cancer/Tumor Profiling Market?